EZN-2279 in Patients With ADA-SCID

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 24, 2014

Primary Completion Date

April 10, 2018

Study Completion Date

May 29, 2019

Conditions
ADA-SCIDAdenosine Deaminase DeficiencySevere Combined Immunodeficiency
Interventions
BIOLOGICAL

EZN-2279

Weekly administration of EZN-2279 via IM injection

BIOLOGICAL

Adagen

Trial Locations (6)

10461

Albert Einstein College of Medicine, The Bronx

14203

UBMD, Buffalo

17033

Penn State College of Medicine The Milton S. Hershey Medical Center, Hershey

90027

Children's Hospital Los Angeles, Los Angeles

94158

University of California San Francisco, San Francisco

80206-2761

National Jewish Health, Denver

Sponsors
All Listed Sponsors
lead

Leadiant Biosciences, Inc.

INDUSTRY

NCT01420627 - EZN-2279 in Patients With ADA-SCID | Biotech Hunter | Biotech Hunter